Celebrex

Celebrex is a brand name of celecoxib, approved by the FDA in the following formulation(s):

CELEBREX (celecoxib - capsule; oral)

• 
  Manufacturer: GD SEARLE
  
  Approval date: December 31, 1998
  
  Strength(s): 100MG, 200MG
  


• 
  Manufacturer: GD SEARLE
  
  Approval date: August 29, 2002
  
  Strength(s): 400MG ^[RLD]


• 
  Manufacturer: GD SEARLE
  
  Approval date: December 15, 2006
  
  Strength(s): 50MG
  

Has a generic version of Celebrex been approved?

No. There is currently no therapeutically equivalent version of Celebrex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Celebrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted pyrazolyl benzenesulfonamides
  Patent 5,466,823
  Issued: November 14, 1995
  Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
  Assignee(s): G.D. Searle & Co.
  A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## or a pharmaceutically-acceptable salt thereof.
  
  Patent expiration dates:
  
  
  • November 30, 2013
    
    ✓ 
    Drug substance
  
  
  
  • May 30, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
  Patent 5,563,165
  Issued: October 8, 1996
  Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
  Assignee(s): G. D. Searl & Co.
  A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1##
  
  Patent expiration dates:
  
  
  • November 30, 2013
    
    ✓ 
    Drug product
  
  
  
  • May 30, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
  Patent 5,760,068
  Issued: June 2, 1998
  Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S. & Docter; Stephen H. & Yu; Stella S.
  Assignee(s): G.D. Searle & Co.
  A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: ##STR1## or a pharmaceutically-acceptable salt thereof.
  
  Patent expiration dates:
  
  
  • June 2, 2015
    
    ✓ 
    Patent use: TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
  
  
  
  • December 2, 2015
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Celebrex Consumer Information (Drugs.com)
• Celebrex Consumer Information (Wolters Kluwer)
• Celebrex Consumer Information (Cerner Multum)
• Celebrex Advanced Consumer Information (Micromedex)
• Celebrex AHFS DI Monographs (ASHP)
• Celecoxib Consumer Information (Drugs.com)
• Celecoxib Consumer Information (Wolters Kluwer)
• Celecoxib Consumer Information (Cerner Multum)
• Celecoxib Advanced Consumer Information (Micromedex)
• Celecoxib AHFS DI Monographs (ASHP)